Up to 30% of people with schizophrenia do not respond to two (or more) trials of
dopaminergic antipsychotics. They are said to have treatment-resistant schizophrenia (TRS) …

Almost fifty years after its first introduction into clinical care, clozapine remains the only
evidence-based pharmacological option for treatment-resistant schizophrenia (TRS), which …

The gene encoding the dopamine transporter (DAT) has been implicated in CNS disorders,
but the responsible polymorphisms remain uncertain. To search for regulatory …

Antipsychotic drugs targeting dopamine neurotransmission are still the principal mean of
therapeutic intervention for schizophrenia. However, about one third of people do not …

Antipsychotic drugs are effective interventions in schizophrenia. However, the efficacy of
these agents often decreases over time, which leads to treatment failure and symptom …

This review presents the findings of pharmacogenetic studies exploring the influence of
gene variants on antipsychotic treatment response, in terms of both symptom improvement …

Background Schizophrenia is a serious mental illness affecting approximately 20 million
individuals globally. Both genetic and environmental factors contribute to the illness. If left …

Background: Clozapine is the recommended antipsychotic for treatment-resistant
schizophrenia (TRS) but there is significant variability between patients in the degree to …

Symptomatic interventions for patients with dementia involve anti-dementia drugs to improve
cognition, psychotropic drugs for the treatment of behavioral disorders (BDs), and different …

Background Stomach pain is an ailment that occurs frequently in the general population. It is
not unusual if such stomach issues produce some amount of stress in an individual, but it …